• Home
  •  / Shanghai Junshi Biosciences

Shanghai Junshi Biosciences

  • Revenue¥1.5 BFY, 2020
  • Market Capitalization$75.4 B2022-05-20

OverviewSuggest Edit

Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company dedicated to the discovery and development of drugs. Its platform technology of protein engineering enables the development of small molecule and macromolecular drugs as well as antibody drug conjugates for the treatment of cancer, autoimmune, and metabolic diseases. In addition, the company engages in the development of biologic drug candidates to treat tumors, psoriasis, multiple sclerosis, osteoporosis, migraine, etc.
TypePublic
Founded2012
Websitejunshipharma.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2020)1,875(+525%)
Revenue (FY, 2020)¥1.5 B(+96%)
Share Price (May 2022)$58
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Shanghai Junshi Biosciences

Feng Hui

Feng Hui

Executive Director and Chief Operations Officer
Zhang Zhuobing

Zhang Zhuobing

Executive Director, Deputy General Manager
Yao Sheng

Yao Sheng

Executive Director, Deputy Generalmanager and Senior Vice President
Li Ning

Li Ning

Executive Director, chief executive officer and general manager
Show more

Shanghai Junshi Biosciences Financials and Metrics

Shanghai Junshi Biosciences Revenue

Shanghai Junshi Biosciences's revenue was reported to be ¥1.5 b in FY, 2020
CNY

Revenue (Q3, 2021)

787.5m

Gross profit (Q3, 2021)

316.1m

Net income (Q3, 2021)

(401.5m)

EBITDA (Q3, 2021)

(517.8m)

EBIT (Q3, 2021)

(388.6m)

Market capitalization (20-May-2022)

75.4b

Closing stock price (20-May-2022)

58.0

Cash (30-Sept-2021)

3.1b

EV

72.9b
Shanghai Junshi Biosciences's current market capitalization is $75.4 b.
Annual
CNYFY, 2018FY, 2019FY, 2020

Revenue

684.0k766.8m1.5b

Cost of goods sold

(2.0m)(90.7m)(372.5m)

Gross profit

(1.3m)677.1m1.2b

R&D expense

(538.2m)(946.1m)(1.8b)
Quarterly
CNYQ1, 2019Q2, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

78.5m226.5m574.9m1.0b1.6b311.5m787.5m

Cost of goods sold

(12.7m)(27.8m)(90.5m)(208.7m)(280.5m)(183.5m)(286.2m)

Gross profit

65.8m199.6m488.5m797.3m1.3b313.2m316.1m

R&D expense

(195.6m)(173.2m)(708.9m)(1.2b)(450.6m)(496.6m)(475.3m)
show all
Annual
CNYFY, 2018FY, 2019FY, 2020

Cash

2.8b1.2b3.4b

Accounts Receivable

6.6m163.2m590.3m

Prepaid Expenses

44.7m297.7m258.2m

Inventories

48.5m180.7m343.4m
Quarterly
CNYQ1, 2019Q2, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

2.5b2.3b676.3m4.1b3.3b4.3b3.1b

Accounts Receivable

85.3m149.4m241.3m402.4m633.3m383.3m697.0m

Prepaid Expenses

113.7m164.3m270.1m269.6m354.7m405.2m469.3m

Inventories

81.3m111.4m274.5m329.0m366.9m414.0m401.4m
show all
Annual
CNYFY, 2018FY, 2019FY, 2020

Net Income

(722.9m)(747.7m)(1.7b)

Depreciation and Amortization

32.7m59.8m119.3m

Inventories

(19.0m)(132.2m)(167.0m)

Accounts Payable

189.9m86.0m686.0m
Quarterly
CNYQ1, 2019Q2, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

(291.2m)9.3m

Depreciation and Amortization

26.6m100.4m

Inventories

(62.9m)(76.5m)

Accounts Payable

49.2m(89.4m)
show all
Show all financial metrics

Shanghai Junshi Biosciences Revenue Breakdown

Embed Graph

Shanghai Junshi Biosciences revenue breakdown by business segment: 71.2% from ANTITUMOR DRUGS and 28.8% from TECHNOLOGY LICENSING INCOME

Shanghai Junshi Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

Learn more about our premium products
SecurityScorecard logo

Shanghai Junshi Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Shanghai Junshi Biosciences Online and Social Media Presence

Shanghai Junshi Biosciences's Trends

Embed Graph

Shanghai Junshi Biosciences News and Updates

June 07, 2020

Shanghai Junshi Biosciences begins human test for experimental coronavirus antibody drug - local paper

Shanghai Junshi Biosciences has started an early-stage study to test its potential antibody treatment against coronavirus in healthy people, official paper Liberation Daily said on its online channel on Sunday. https://bit.ly/3eZhSWM

 Shanghai Junshi Biosciences Frequently Asked Questions

  • When was Shanghai Junshi Biosciences founded?

    Shanghai Junshi Biosciences was founded in 2012.

  • Who are Shanghai Junshi Biosciences key executives?

    Shanghai Junshi Biosciences's key executives are Feng Hui, Zhang Zhuobing and Yao Sheng.

  • How many employees does Shanghai Junshi Biosciences have?

    Shanghai Junshi Biosciences has 1,875 employees.

  • What is Shanghai Junshi Biosciences revenue?

    Latest Shanghai Junshi Biosciences annual revenue is ¥1.5 b.

  • What is Shanghai Junshi Biosciences revenue per employee?

    Latest Shanghai Junshi Biosciences revenue per employee is ¥799.8 k.

  • Who are Shanghai Junshi Biosciences competitors?

    Competitors of Shanghai Junshi Biosciences include ZAI Lab, Taiho Pharmaceutical and Biocon.